| By Ben Adams Although AstraZeneca and Moderna are archrivals in the COVID-19 vaccine space, the two have an interesting mRNA pact that has been operating largely under the radar. read more |
| |
|---|
|
| By Conor Hale A large-scale clinical trial of Fitbit’s pulse-tracking algorithm showed success in spotting the hidden signs of atrial fibrillation, demonstrating the capability of smartwatches and fitness trackers as a frontline screening device for the potentially dangerous heart condition. read more |
| |
|---|
|
| By Fraiser Kansteiner J&J's type 2 diabetes med Invokana helped improve patients' heart failure symptoms regardless of whether or not they had diabetes, phase 3 data presented at the American Heart Association's virtual Scientific Sessions 2021 showed. read more |
| |
|---|
|
| By Annalee Armstrong Bristol Myers took the rare step of tapping Johnson & Johnson’s Janssen unit to help develop new anticoagulant medicines back in 2018. Now, the Big Pharmas have the proof-of-concept data they need to prepare the partnership for late stage development. read more |
| |
|---|
|
| By Kevin Dunleavy Three months after earning an approval to treat chronic heart failure with Jardiance, Eli Lilly and Boehringer Ingelheim have posted data that show the drug’s effectiveness against another type of heart failure. read more |
| |
|---|
|
| By Emmy Lucas PhaseBio had already shown its Brilinta reversal agent could work in healthy volunteers, but now the biotech has the phase 3 data to back up the therapy's use in patients who are in an emergency situation. read more |
| |
|---|
|
| By Annalee Armstrong Turns out Bristol Myers Squibb’s targeted heart drug mavacamten gets along pretty well with traditional beta blocker therapies that are often used to control blood pressure. This is key as BMS pads the case for an approval of the therapy picked up through the $13 billion acquisition of MyoKardia just over a year ago. read more |
| |
|---|
|
|
|
